Clinical Trends for January 2017

Ryan Syrek


January 27, 2017

Clinical Trend of the Week (December 31-January 6): Ocrelizumab

An OPERA is responsible for this week's top search term. Specifically, results from the OPERA 1, OPERA 2, and ORATORIO randomized controlled trials were recently published. They show that the humanized monoclonal antibody ocrelizumab was effective in reducing disease activity and progression in patients with relapsing multiple sclerosis (MS) or primary progressive MS. The findings are being met with excitement and optimism, even if longer-term studies are required to consider side effects and other concerns. The potential for a new treatment in patients with this challenging condition no doubt resulted in this week's top clinical trend.

For more information on Multiple Sclerosis, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.